Adrenergic receptors modulate motoneuron excitability, sensory synaptic transmission and muscle spasms after chronic spinal cord injury.
The brain stem provides most of the noradrenaline (NA) present in the spinal cord, which functions to both increase spinal motoneuron excitability and inhibit sensory afferent transmission to motoneurons (excitatory postsynaptic potentials; EPSPs). NA increases motoneuron excitability by facilitating calcium-mediated persistent inward currents (Ca PICs) that are crucial for sustained motoneuron firing. Spinal cord transection eliminates most NA and accordingly causes an immediate loss of PICs and emergence of exaggerated EPSPs. However, with time PICs recover, and thus the exaggerated EPSPs can then readily trigger these PICs, which in turn produce muscle spasms. Here we examined the contribution of adrenergic receptors to spasms in chronic spinal rats. Selective activation of the α(1A) adrenergic receptor with the agonists methoxamine or A61603 facilitated Ca PIC and spasm activity, recorded both in vivo and in vitro. In contrast, the α(2) receptor agonists clonidine and UK14303 did not facilitate Ca PICs, but did decrease the EPSPs that trigger spasms. Moreover, in the absence of agonists, spasms recorded in vivo were inhibited by the α(1) receptor antagonists WB4010, prazosin, and REC15/2739, and increased by the α(2) receptor antagonist RX821001, suggesting that both adrenergic receptors were endogenously active. In contrast, spasm activity recorded in the isolated in vitro cord was inhibited only by the α(1) antagonists that block constitutive receptor activity (activity in the absence of NA; inverse agonists, WB4010 and prazosin) and not by the neutral antagonist REC15/2739, which only blocks conventional NA-mediated receptor activity. RX821001 had no effect in vitro even though it is an α(2) receptor inverse agonist. Our results suggest that after chronic spinal cord injury Ca PICs and spasms are facilitated, in part, by constitutive activity in α(1) adrenergic receptors. Additionally, peripherally derived NA (or similar ligand) activates both α(1) and α(2) adrenergic receptors, controlling PICs and EPSPs, respectively.
Centre for Neuroscience, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.
M M
MM
Rank
K C
KC
Murray
M J
MJ
Stephens
J
J
D'Amico
M A
MA
Gorassini
D J
DJ
Bennett
D000322:Adrenergic Agonists / Q000494:pharmacology; D018674:Adrenergic Antagonists / Q000494:pharmacology; D000818:Animals; D002867:Chromones / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000502:physiology; D005260:Female; D019329:Idazoxan / Q000031:analogs & derivatives / Q000494:pharmacology; D023421:Models, Animal; D009046:Motor Neurons / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011941:Receptors, Adrenergic / Q000187:drug effects / Q000502:physiology*; D011984:Sensory Receptor Cells / Q000502:physiology*; D013035:Spasm / Q000209:etiology / Q000503:physiopathology*; D013119:Spinal Cord Injuries / Q000150:complications / Q000503:physiopathology*; D009435:Synaptic Transmission / Q000502:physiology*
D000322:Adrenergic Agonists; D018674:Adrenergic Antagonists; D002867:Chromones; C099870:Rec 15-2739; D011941:Receptors, Adrenergic; C058525:2-methoxyidazoxan; D003000:Clonidine; D009638:Norepinephrine; D011224:Prazosin; D019329:Idazoxan